A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

Conditions

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Finerenone (BAY94-8862 ) 10 mg — DRUG
  oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
• Empagliflozin — DRUG
  oral administration, once daily
• Empagliflozin Placebo — DRUG
  Matching placebo to empagliflozin oral administration, once daily
• Finerenone (BAY94-8862 ) 20 mg — DRUG
  oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
• Finerenone Placebo — DRUG
  Matching Placebo to Finerenone oral administration once daily

Study Details

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone. Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times. The study team will: * collect blood and urine samples * check the participants' vital signs * do a physical examination including height and weight * check the participants' heart health by using an electrocardiogram (ECG) * monitor the participants' blood pressure * ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.

Key Dates

Start date

Jun 23, 2022

Status verified

Mar 2025

Primary completion

Mar 14, 2025

Completion

Mar 14, 2025

Study Design

Enrollment

1,664 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Finerenone and Empagliflozin
  Participants will take Finerenone (10 or 20 mg once daily \[OD\]) and Empagliflozin (10 mg OD) for up to 180 days.
• Experimental: Finerenone and Empagliflozin placebo
  Participants will take Finerenone (10 or 20 mg OD) and matching placebo to Empagliflozin (OD) for up to 180 days.
• Experimental: Empagliflozin and Finerenone placebo
  Participants will take Empagliflozin (10 mg OD) and matching placebo to Finerenone (OD). for up to 180 days.

Primary Outcome Measure

Relative change from baseline in UACR at 180 days in combination therapy group versus empagliflozin alone [ Time Frame: Up to 180 days ]

Locations (49)

Find similar trials in Surprise, AZ

Related Studies

• Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
  Recruiting · Johns Hopkins Bloomberg School of Public Health · Kansas City, Missouri
• University of Michigan "Nephrology Research BioBank"
  Recruiting · University of Michigan · Ann Arbor, Michigan
• Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
  Recruiting · University of Michigan · Ann Arbor, Michigan
• Sympatholysis in Chronic Kidney Disease
  PHASE1 · Recruiting · Emory University · Decatur, Georgia